REVIEW AND COMMENT Toxicogenomics in Risk Assessment: Applications and Needs

Since its inception, there have been high expectations for the science of toxicogenomics to decrease the uncertainties associated with the risk assessment process by providing valuable insights into toxic mechanisms of action. However, the application of these data into risk assessment practices is still in the early stages of development, and proof of principle experiments have yet to emerge. The following discusses some potential applications as well as impediments that warrant a concerted investigation from allstakeholdersinordertofacilitate theacceptance andsubsequent incorporation of toxicogenomics into regulatory decision making.

[1]  Jason E. Stewart,et al.  Design and implementation of microarray gene expression markup language (MAGE-ML) , 2002, Genome Biology.

[2]  Mark D. Johnson,et al.  A gene expression signature for oxidant stress/reactive metabolites in rat liver. , 2004, Biochemical pharmacology.

[3]  Zheng Li,et al.  Inferring pathways and networks with a Bayesian framework , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  Weida Tong,et al.  Development of public toxicogenomics software for microarray data management and analysis. , 2004, Mutation research.

[5]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[6]  L. Lesko,et al.  Microarray data—the US FDA, industry and academia , 2003, Nature Biotechnology.

[7]  George Stephanopoulos,et al.  Inverse modeling using multi-block PLS to determine the environmental conditions that provide optimal cellular function , 2004, Bioinform..

[8]  Janice Hopkins Tanne.  The Genomic Revolution , 2001, BMJ : British Medical Journal.

[9]  J. Tuomisto.  Is the precautionary principle used to cover up ignorance? , 2004, Basic & clinical pharmacology & toxicology.

[10]  Lee Bennett,et al.  Prediction of compound signature using high density gene expression profiling. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[11]  Homin K. Lee,et al.  Coexpression analysis of human genes across many microarray data sets. , 2004, Genome research.

[12]  Emanuel F. Petricoin,et al.  Medical applications of microarray technologies: a regulatory science perspective , 2002, Nature Genetics.

[13]  Eric A G Blomme,et al.  Toxicogenomics in drug discovery: from preclinical studies to clinical trials. , 2004, Chemico-biological interactions.

[14]  Raymond S H Yang,et al.  Chemical mixtures research: significance and future perspectives. , 2002, Environmental health perspectives.

[15]  R G Ulrich,et al.  Clustering of hepatotoxins based on mechanism of toxicity using gene expression profiles. , 2001, Toxicology and applied pharmacology.

[16]  Lee Bennett,et al.  Gene expression analysis reveals chemical-specific profiles. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[17]  Kris Freeman,et al.  Toxicogenomics Data: The Road to Acceptance , 2004, Environmental health perspectives.

[18]  S. Hilsenbeck,et al.  Genomic approaches in the management and treatment of breast cancer , 2005, British Journal of Cancer.

[19]  Gavin Sherlock,et al.  Funding high-throughput data sharing , 2004, Nature Biotechnology.

[20]  Samuel H. Wilson,et al.  Environmental health and genomics: visions and implications , 2000, Nature Reviews Genetics.

[21]  R. Dunn,et al.  Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.

[22]  Weida Tong,et al.  QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies , 2004, Expert review of molecular diagnostics.

[23]  M. Gerstein,et al.  Annotation transfer between genomes: protein-protein interologs and protein-DNA regulogs. , 2004, Genome research.

[24]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[25]  M. Gerstein,et al.  Genomic analysis of regulatory network dynamics reveals large topological changes , 2004, Nature.

[26]  Francois Pognan,et al.  Genomics, proteomics and metabonomics in toxicology: hopefully not 'fashionomics'. , 2004, Pharmacogenomics.

[27]  R. Lempicki,et al.  Evaluation of gene expression measurements from commercial microarray platforms. , 2003, Nucleic acids research.

[28]  Christina Chan,et al.  Integrating Gene Expression and Metabolic Profiles* , 2004, Journal of Biological Chemistry.

[29]  E. Dougherty,et al.  Unraveling gene-gene interactions regulated by ligands of the aryl hydrocarbon receptor. , 2004, Environmental health perspectives.

[30]  R. Paules,et al.  Phenotypic anchoring: linking cause and effect. , 2003, Environmental health perspectives.

[31]  Masahiro Yamamura,et al.  Use of Genetic Profiling in Leprosy to Discriminate Clinical Forms of the Disease , 2003, Science.

[32]  S. Dwight,et al.  Predicting gene function from patterns of annotation. , 2003, Genome research.

[33]  C. Ball,et al.  Submission of Microarray Data to Public Repositories , 2004, PLoS biology.

[34]  Andrew Emili,et al.  Integrating gene and protein expression data: pattern analysis and profile mining. , 2005, Methods.

[35]  Hiroaki Kitano,et al.  The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models , 2003, Bioinform..

[36]  R G Ulrich,et al.  Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity. , 2001, Toxicology letters.

[37]  P. Lord.  Progress in applying genomics in drug development. , 2003, Toxicology letters.

[38]  M. Cunningham,et al.  Applying toxicogenomics in mechanistic and predictive toxicology. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[39]  Valérie Zuang,et al.  A Modular Approach to the ECVAM Principles on Test Validity , 2004, Alternatives to laboratory animals : ATLA.

[40]  James R. Knight,et al.  A Protein Interaction Map of Drosophila melanogaster , 2003, Science.

[41]  Shiew-Mei Huang,et al.  Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA‐PWG‐PhRMA‐DruSafe Workshop , 2003, Journal of clinical pharmacology.

[42]  Joshua M. Stuart,et al.  A Gene-Coexpression Network for Global Discovery of Conserved Genetic Modules , 2003, Science.

[43]  R. Tennant,et al.  The National Center for Toxicogenomics: using new technologies to inform mechanistic toxicology. , 2002, Environmental health perspectives.

[44]  John Quackenbush.  Microarray data normalization and transformation , 2002, Nature Genetics.

[45]  J. DiMasi.  New drug development in the United States from 1963 to 1999 , 2001, Clinical pharmacology and therapeutics.

[46]  Gert Lubec,et al.  Limitations of current proteomics technologies. , 2005, Journal of chromatography. A.

[47]  C. Travis,et al.  The Genomic Revolution: What Does It Mean for Risk Assessment? , 2001, Risk analysis : an official publication of the Society for Risk Analysis.

[48]  Hans Lehrach,et al.  A comparison of oligonucleotide and cDNA-based microarray systems. , 2004, Physiological genomics.

[49]  Gert R. G. Lanckriet,et al.  Classification of a large microarray data set: algorithm comparison and analysis of drug signatures. , 2005, Genome research.

[50]  David Tuck,et al.  White Paper: Training the Next Generation of Informaticians: The Impact of "BISTI" and Bioinformatics - A Report from the American College of Medical Informatics , 2004, J. Am. Medical Informatics Assoc..

[51]  R. Ulrich,et al.  Overview of an interlaboratory collaboration on evaluating the effects of model hepatotoxicants on hepatic gene expression. , 2004, Environmental health perspectives.

[52]  Ushering in the New Toxicology: Toxicogenomics and the Public Interest , 2005, Environmental health perspectives.

[53]  A. Li,et al.  Screening for human ADME/Tox drug properties in drug discovery. , 2001, Drug discovery today.

[54]  Thomas J. Begley,et al.  Global network analysis of phenotypic effects: Protein networks and toxicity modulation in Saccharomyces cerevisiae , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[55]  J. Woodcock,et al.  Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective , 2004, Nature Reviews Drug Discovery.

[56]  Rolf Apweiler,et al.  The Proteomics Standards Initiative , 2003, Proteomics.

[57]  P Smith,et al.  Concordance of the toxicity of pharmaceuticals in humans and in animals. , 2000, Regulatory toxicology and pharmacology : RTP.

[58]  H. Hellmold,et al.  2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the mRNA expression of critical genes associated with cholesterol metabolism, bile acid biosynthesis, and bile transport in rat liver: a microarray study. , 2005, Toxicology and applied pharmacology.

[59]  Henrik Antti,et al.  Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMET project. , 2003, Toxicology and applied pharmacology.

[60]  Carole L Yauk,et al.  Comprehensive comparison of six microarray technologies. , 2004, Nucleic acids research.

[61]  William S Stokes,et al.  The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM): Recent Progress in the Evaluation of Alternative Toxicity Testing Methods , 2003 .

[62]  S. L. Wong,et al.  A Map of the Interactome Network of the Metazoan C. elegans , 2004, Science.

[63]  Gary D Bader,et al.  Global Mapping of the Yeast Genetic Interaction Network , 2004, Science.

[64]  J. DiMasi,et al.  Risks in new drug development: Approval success rates for investigational drugs , 2001, Clinical pharmacology and therapeutics.

[65]  T. Singer,et al.  Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit? , 2005, Mutation research.

[66]  Mark W. Craven,et al.  Identification of toxicologically predictive gene sets using cDNA microarrays. , 2001, Molecular pharmacology.

[67]  D. Kell.  Metabolomics and systems biology: making sense of the soup. , 2004, Current opinion in microbiology.

[68]  Silvio Albertini,et al.  Discriminating Different Classes of Toxicants by Transcript Profiling , 2004, Environmental health perspectives.

[69]  M. Fielden,et al.  Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. , 2005, Journal of biotechnology.

[70]  Mark Craven,et al.  Interaction Networks in Yeast Define and Enumerate the Signaling Steps of the Vertebrate Aryl Hydrocarbon Receptor , 2004, PLoS biology.

[71]  Purvesh Khatri,et al.  Ontological analysis of gene expression data: current tools, limitations, and open problems , 2005, Bioinform..

[72]  Yu Rang Park,et al.  GOChase: correcting errors from Gene Ontology-based annotations for gene products , 2005, Bioinform..

[73]  Nigel W. Hardy,et al.  Summary recommendations for standardization and reporting of metabolic analyses , 2005, Nature Biotechnology.